Complementary and Alternative Medicine and the Management of the Metabolic Syndrome

Journal of the American Dietetic Association

Volumn 108, Issue 3, 2008, Pages 495-509

  Hollander, Jason M ^a   Mechanick, Jeffrey I ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE MEDICINE; ARTICLE; DIET SUPPLEMENTATION; DIET THERAPY; EVIDENCE BASED MEDICINE; HUMAN; LIFESTYLE; METABOLIC SYNDROME X; METHODOLOGY; PHYTOTHERAPY; TREATMENT OUTCOME; UNITED STATES;

COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; HUMANS; LIFE STYLE; METABOLIC SYNDROME X; NUTRITION THERAPY; PHYTOTHERAPY; TREATMENT OUTCOME; UNITED STATES;

EID: 39649103205     PISSN: 00028223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jada.2007.12.007     Document Type: Article

References (131)

1. Mechanick J.I. Methods of creative cognition in medical diagnosis. Mt Sinai J Med 54 (1987) 348-354
2. Eisenberg D.M., Davis R.B., Ettner S.L., Appel S., Wilkey S., Van Rompay M., and Kessler R.C. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA 280 (1998) 1569-1575
3. Aberti K.G., and Zimmet P.Z. Definition, diagnosis, and classifciation of diabetes mellitus and its complications, part 1: Diagnosis and classification of diabetes mellitus: Provisional report of WHO consultation. Diabet Med 15 (1998) 539-553
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
5. Alberti K.G., Zimmet P., and Shaw J. The metabolic syndrome-A new world wide definition. Lancet 366 (2005) 1059-1062
6. Grundy S.M., Brewer Jr. H.B., Cleeman J.L., Smith Jr. S.C., and Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
7. Klein B.E., Klein R., and Lee K.E. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care 25 (2002) 1790-1794
8. Abassi F., Brown B.W., Lamendola C., McLaughlin T., and Reaven G.M. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 40 (2002) 937-943
9. Einhorn D., Reaven G.M., Cobin R.H., Ford E., Ganda O.P., Handelsman Y., Hellman R., Jellinger P.S., Kendall D., Krauss R.M., Neufeld N.D., Petak S.M., Rodbard H.W., Seibel J.A., Smith D.A., and Wilson P.W. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9 (2003) 237-252
10. Johnson L.W., and Weinstock R.S. The metabolic syndrome: Concepts and controversy. Mayo Clin Proc 81 (2006) 1516-1520
11. Bays H., Blonde L., and Rosenson R. Adiposopathy: How do diet, exercise, and weight loss drug therapies improve metabolic disease in overweight patients. Expert Rev Cardiovasc Ther 4 (2006) 871-895
12. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D.S., Haffner S.M., Isles C., Macfarlane P.W., Packard C.J., Cobbe S.M., and Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
13. Ford E.S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the United States. Diabetes Care 28 (2005) 2745-2749
14. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., and Salonen J.T. The metabolic syndrome and total cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
15. Saito T., Misawa K., and Kawata S. Fatty liver and non-alcoholic steatohepatitis. Intern Med 46 (2007) 101-103
16. Lastra G., Manrique C., and Sowers J.R. Obesity, cardiometabolic syndrome, and chronic kidney disease: The weight of the evidence. Adv Chronic Kidney Dis 13 (2006) 365-373
17. Rader D.J. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 120 suppl 1 (2007) S12-S18
18. Alam I., Lewis K., Stephens J.W., and Baxter J.N. Obesity, metabolic syndrome and sleep apnea: All proinflammatory states. Obes Rev 8 (2007) 119-127
19. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., Keinanen-Kiukaanniemi S., Laakso M., Louheranta A., Rastas M., Salminen V., and Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
20. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., and Nathan D.M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
21. Orchard T.J., Temprosa M., Goldberg R., Haffner S., Ratner R., Marcovina S., and Fowler S. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program randomized trial. Ann Intern Med 142 (2005) 611-619
22. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risks patients. The Heart Outcome Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
23. Kjeldsen S.E., Dahlof B., Devereux R.B., Julius S., Aurup P., Edelman J., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristianson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Snapinn S., and Wedel H. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 288 (2002) 1491-1498
24. Knowler W.C., Barrett-Connor E., Folwer S.E., Hamman R.F., Lachin J.M., Walker E.A., and Nathan D.M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
25. Mechanick J.I. The rational use of dietary supplements and nutraceutricals in clinical medicine. Mt Sinai J Med 72 (2005) 161-165
26. Mechanick J.I. The rational use of dietary supplements, nutraceuticals, and functional foods for the diabetic and prediabetic patient. In: Mechanick J.I., and Brett E.M. (Eds). Nutritional Strategies for the Diabetic and Prediabetic Patient (2006), Taylor and Francis Group, Boca Raton, FL 265-267
27. Zeisel S.H. Regulation of "Nutraceuticals.". Science 285 (1999) 1853-1855
28. Dietary Supplement Health and Education Act of 1994. Pub L No. 103-417.
29. Mechanick J.I., Brett E.M., Chausmer A.B., Dickey R.A., and Wallach S. American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals. Endocr Pract 5 (2003) 417-470
30. Mayer K., Grimm H., Grimminger F., and Seeger W. Parenteral nutrition with n-3 lipids in sepsis. Br J Nutr 87 suppl 1 (2002) S69-S75
31. Macdonald A. Omega-3 fatty acids as adjunctive therapy in Crohns disease. Gastroenterol Nurs 29 (2006) 295-301
32. Pittler M.H., and Ernst E. Complementary therapies for peripheral arterial disease: Systematic review. Atherosclerosis 181 (2005) 1-7
33. Leaf A. Prevention of sudden cardiac death by n-3 polyunsaturated fatty acids. Fundam Clin Pharmacol 20 (2006) 525-558
34. McKenney J.M., and Sica D. Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. Am J Health Syst Pharm 64 (2007) 595-605
35. Park Y., and Harris W.S. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 44 (2004) 455-463
36. Griffin M.D., Sanders T.A., Davies I.G., Morgan L.M., Millward D.J., Lewis F., Slaughter S., Cooper J.A., Miller G.J., and Griffin B.A. Effects of altering the ratio of n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45-70 y: The OPTILIP study. Am J Clin Nutr 84 (2006) 1290-81298
37. Bronsgeest-Schoute H.C., van Gent C.M., Luten J.B., and Ruiter A. The effect of various intakes of omega 3 fatty acids on the blood lipid composition in healthy human subjects. Am J Clin Nutr 34 (1981) 1752-1757
38. Laidlaw M., and Holub B.J. Effects of supplementation with fish oil-derived n-3 fatty acids and gamma-linolenic acid on circulating plasma lipids and fatty acid profile in women. Am J Clin Nutr 77 (2003) 37-42
39. Rivellese A.A., Maffettone A., Iovine C., DiMarino L., Annuzzi G., Mancini M., and Riccardi G. Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. Diabetes Care 19 (1996) 1207-1213
40. Harris W.S., Windsor S.L., and Dujovne C.A. Effects of four doses of n-3 fatty acids given to hyperlipidemic patients for six months. J Am Coll Nutr 10 (1991) 220-227
41. Harris W.S., Ginsberg H.N., Arunakul N., Shachter N.S., Windsor S.L., Adams M., Berglund L., and Osmundsen K. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 4 (1997) 385-391
42. Pownall H.J., Brauchi D., Kilinc C., Osmundsen K., Pau Q., Payton-Ross C., Gotto Jr. A.M., and Ballantyne C.M. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 143 (1999) 285-297
43. Durrington P.N., Bhatnagar D., Mackness M.I., Morgan J., Julier K., Khan M.A., and France M. An omega-3 polyunsaturated fatty acid concentrate administered for 1 year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridemia. Heart 85 (2001) 544-548
44. McVeigh B.L., Dillingham B.L., Lampe J.W., and Duncan A.M. Effect of soy protein varying in isoflavone content on serum lipids in healthy young men. Am J Clin Nutr 83 (2006) 244-251
45. Hoie L.H., Morgenstern E.C., Gruenwald J., Braubaum H.J., Busch R., Luder W., and Zunft H.J. A double-blind placebo-controlled clinical trial compares the cholesterol-lowering effects of two different soy protein preparations in hypercholesterolemic subjects. Eur J Nutr 44 (2005) 65-71
46. Engleman H.M., Alekel D.L., Hanson L.N., Kanthasamy A.G., and Reddy M.B. Blood lipid and oxidative stress responses to soy protein with isoflavones and phytic acid in postemenopausal women. Am J Clin Nutr 81 (2005) 590-596
47. Hermansen K., Hansen B., Jacobsen R., Clausen P., Dalgaard M., Dinesen B., Holst J.J., Pedersen E., and Astrup A. Effects of soy supplementation on blood lipids and arterial function in hypercholesterolaemic subjects. Eur J Clin Nutr 59 (2005) 843-850
48. Kreijkamp-Kaspsers S., Kok L., Grobbee D.E., de Haan E.H., ALeman A., Lampe J.W., and van der Schouw Y.T. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: A randomized controlled trial. JAMA 292 (2004) 65-74
49. Reynolds K., Chin A., Lees K.A., Nguyen A., Bujnowski D., and He J. A meta-analysis of the effect of soy protein supplementation on serum lipids. Am J Cardiol 98 (2006) 633-640
50. Zhan S., and Ho S.C. Meta-analysis of the effects of soy protein containing isoflavones on lipid profile. Am J Clin Nutr 81 (2005) 397-408
51. Weggemans R.M., and Traustwein E.A. Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: A meta-analysis. Eur J Clin Nutr 57 (2003) 940-946
52. Anderson J.W., Johnstone B.M., and Cook-Newell M.E. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 333 (1995) 276-282
53. Jenkins D.J., Kendall C.W., Vuksan V., Vidgen E., Parker T., Faulkner D., Mehling C.C., Garsetti M., Testolin G., Cunnane S.C., Ryan M.A., and Corey P.N. Soluble fiber intake at a dose approved by the US Food and Drug Administration for a claim of health benefits: Serum lipid risk factors for cardiovascular disease assessed in a randomized controlled crossover trial. Am J Clin Nutr 75 (2002) 834-839
54. Anderson J.W., Davidson M.H., Blonde L., Brown W.V., Howard W.J., Ginsberg H., Allgood L.D., and Weingand K.W. Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. Am J Clin Nutr 71 (2000) 1433-1438
55. Romero A.L., Romero J.E., Galaviz S., and Fernandez M.L. Cookies enriched with psyllium or oatbran lower plasma LDL cholesterol in normal and hypercholesterolemic men from northern Mexico. J Am Coll Nutr 17 (1998) 601-608
56. Davidson M.H., Maki K.C., Kong J.C., Dugan L.D., Torri S.A., Hall H.A., Drennan K.B., Anderson S.M., Fulgoni V.L., Saldanha L.G., and Olson B.H. Long-term effects of consuming foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemia. Am J Clin Nutr 67 (1998) 367-376
57. Davidson M.H., Dugan L.D., Burns J.H., Sugimoto D., Story K., and Drennan K. A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: A controlled, double-blind, crossover study. Am J Clin Nutr 63 (1996) 96-102
58. Anderson J.W., Allgood L.D., Lawrence A., Altringer L.A., Jerdack G.R., Hengehold D.A., and Morel J.G. Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: Meta-analysis of 8 controlled trials. Am J Clin Nutr 71 (2000) 472-479
59. Brown L., Rosner B., Willett W.W., and Sacks F.M. Cholesterol-lowering effects of dietary fiber: A meta-analysis. Am J Clin Nutr 69 (1999) 30-42
60. Olson B.H., Anderson S.M., Becker M.P., Anderson J.W., Hunninghake D.B., Jenkins D.J., LaRosa J.C., Rippe J.M., Roberts D.C., Stoy D.B., Summerbell C.D., Truswell A.S., Wolever T.M., Morris D.H., and Fulgoni V.L. Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol, in hypercholesterolemic adults: Results of a meta-analysis. J Nutr 127 (1997) 1973-1980
61. Grassi D., Necozione S., Lippi C., Croce G., Valeri L., Pasqualetti P., Desideri G., Blumber J.B., and Ferri C. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension 46 (2005) 398-405
62. Grassi D., Lippi C., Necozione S., Desideri G., and Ferri C. Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am J Clin Nutr 81 (2005) 611-614
63. Brand-Miller J., Holt S.H., de Jong V., and Petocz P. Cocoa powder increases postprandial insulinemia in lean young adults. J Nutr 133 (2003) 3149-3152
64. Steinberg F.M., Bearden M.M., and Keen C.L. Cocoa and chocolate flavonoids: Implications for cardiovascular health. J Am Diet Assoc 103 (2003) 214-223
65. Keen C.L. Chocolate: Food as medicine/medicine as food. J Am Coll Nutr 20 suppl 5 (2001) 436S-439S
66. Keen C.L., Holt R.R., Oteiza P.I., Fraga C.G., and Schmitz H.H. Cocoa antioxidants and cardiovascular health. Am J Clin Nutr 81 suppl (2005) 298S-303S
67. Nguyen N.U., Henriet M.T., Dumoulin G., Widmer A., and Regnard J. Increase in calciuria and oxaluria after a single chocolate bar load. Horm Metab Res 26 (1994) 383-386
68. Konrat C., Mennen L.I., Caces E., Lepinay P., Rakotozafy F., Forhan A., and Balkau B. Alcohol intake and fasting insulin in French men and women. The DESIR study. Diabetes Metab 28 (2002) 116-123
69. Wannamethee S.G., Lowe G.D., Shaper G., Whincup P.H., Rumley A., Walker M., and Lennon L. The effects of different alcoholic drinks on lipids, insulin and haemostatic and inflammatory markers in old men. Thromb Haemost 90 (2003) 1080-1087
70. Hodge A.M., English D.R., O'Dea K., and Giles G.G. Alcohol intake, consumption pattern and beverage type, and the risk of type 2 diabetes. Diabet Med 23 (2006) 690-697
71. Wei M., Gibbons L.W., Mitchell T.L., Kampert J.B., and Blair S.N. Alcohol intake and incidence of type 2 diabetes in men. Diabetes Care 23 (2000) 18-22
72. Hu F.B., Manson J.E., Stampfer M.H., Colditz G., Liu S., Solomon C.G., and Willett W.C. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345 (2001) 790-797
73. Conigrave K.M., Hu B.F., Camargo Jr. C.A., Stampfer M.J., Willett W.C., and Rimm E.B. A prospective study of drinking patterns in relation to risk of type 2 diabetes among men. Diabetes 50 (2001) 2390-2395
74. Napoli R., Cozzolino D., Guardasole V., Angelini V., Zarra E., Matarazzo M., Cittadini A., Sacca L., and Torella R. Red wine consumption improves insulin resistance but not endothelial function in type 2 diabetic patients. Metabolism 54 (2005) 306-313
75. Kokavec A., and Crowe S.F. Effect on plasma insulin and plasma glucose of consuming white wine alone after a meal. Alcohol Clin Exp Res 27 (2003) 1718-1723
76. Perez-Vizcaino F., Duarte J., and Andriantsitohaina R. Endothelial function and cardiovascular disease: Effects of quercetin and wine polyphenols. Free Radic Res 40 (2006) 1054-1065
77. Zern T.L., and Fernandez M.L. Cardioprotective effects of dietary polyphenols. J Nutr 135 (2005) 2291-2294
78. Rahman I., Biswas S.K., and Kierkham P.A. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol 72 (2006) 1439-1452
79. Ceccanti M., Attili A., Balducci G., Attilia F., Giacomelli S., Rotondo C., Sasso G.F., Xirouchakis E., and Attilia M.L. Acute alcoholic hepatitis. J Clin Gastroenterol 40 (2006) 833-841
80. Otsuki M., and Tashiro M. Chronic pancreatitis and pancreatic cancer, lifestyle-related diseases. Intern Med 46 (2007) 109-113
81. Preedy V.R., Adachi J., Ueno Y., Ahmed S., Mantle D., Mullatti N., Rajendram R., and Peters T.J. Alcoholic skeletal muscle myopathy: Definitions, features, contribution of neuropathy, impact and diagnosis. Eur J Neurol 8 (2001) 677-687
82. Holmes R.S., and Vaughan T.L. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 17 (2007) 2-9
83. Puddey I.B., and Beilin L.J. Alcohol is bad for blood pressure. Clin Exp Pharmacol Physiol 33 (2006) 847-852
84. Fabbri A., Marchesini G., Morselli-Labate A.M., Rossi F., Cicognani A., Dente M., Iervese T., Ruggeri S., Mengozzi U., and Vandelli A. Positive blood alcohol concentration and road accidents. A prospective study in an Italian emergency department. Emerg Med J 19 (2002) 210-214
85. Schwarz K., and Mertz W. Chromium (III) and the glucose tolerance factor. Arch Biochem Biophys 85 (1959) 292-295
86. Jeejeebhoy K.N., Chu R.C., Marliss E.B., Greenberg G.R., and Bruce-Robertson A. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term parenteral nutrition. Am J Clin Nutr 30 (1977) 531-538
87. Cefalu W.T., and Hu F.B. Role of chromium in human health and diabetes. Diabetes Care 27 (2004) 2741-2751
88. Anderson R.A., Cheng N., Bryden N.A., Polansky M.M., Cheng N., Chi J., and Feng J. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 46 (1997) 1786-1791
89. Amato P., Morales A.J., and Yen S.S. Effects of chromium picolinate supplementation on insulin sensitivity, serum lipids, and body composition in healthy, nonobese, older men and women. J Gerontol A Biol Sci Med Sci 55 (2000) M260-M263
90. Jovanovic L., Gutierrez M., and Peterson C.M. Chromium supplementation for women with gestational diabetes mellitus. J Tace Elem Exp Med 12 (1999) 91-97
91. Ravina A., Slezak L., Mirsky N., Bryden N.A., and Anderson R.A. Reversal of corticosteroid-induced diabetes mellitus with supplemental chromium. Diabet Med 16 (1999) 164-167
92. Morris B.W., Kouta S., Robinson R., MacNeil S., and Heller S. Chromium supplementation improves insulin resistance in patients with type 2 diabetes mellitus. Diabet Med 17 (2000) 684-685
93. Cheng N., Zhu X., Shi H., Wu W., Chi J., Cheng J., and Anderson R.A. Follow-up survey of people in China with type 2 diabetes mellitus consuming supplemental chromium. J Trace Elem Exp Med 12 (1999) 55-60
94. Althuis M.D., Jordan N.E., Ludington E.A., and Witts J.T. Glucose and insulin responses to dietary chromium supplements: a meta-analysis. Am J Clin Nutr 76 (2002) 148-155
95. Martin J., Wang Z.Q., Zhang X.H., Wachtel D., Volaufova J., Matthews D.E., and Cefalu W.T. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 29 (2006) 1826-1832
96. Kleefstra N., Houweling S.T., Jansman F.G., Groenier K.H., Gans R.O., Meyboom-de Jong B., Bakker S.J., and Bilo H.J. Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: A randomized, double-blind, placebo-controlled trial. Diabetes Care 29 (2006) 521-525
97. Azadbakht L., Mirmiran P., Esmaillzadeh A., Azizi T., and Azizi F. Beneficial effects of Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care 28 (2005) 2823-2831
98. Appel L.J., Moore T.J., Obarzanek E., Vollmer W.M., Svetkey L.P., Sacks F.M., Bray G.A., Vogt T.M., Cutler J.A., Windhauser M.M., Lin P.H., and Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 336 (1997) 1117-1124
99. Teragawa H., Kato M., Yamagat T., Matsuura H., and Kajiyama G. Magnesium causes nitric oxide independent coronary artery vasodilation in humans. Heart 86 (2001) 212-216
100. Muir K.W., Lees K.R., Ford I., and Davis S. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke Trial): Randomized controlled trial. Lancet 363 (2004) 439-445
101. Ma J., Folsom A.R., Melnick S.L., Eckfeldt J.H., Sharrett A.R., Nabulsi A.A., Hutchinson R.G., and Metcalf P.A. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: The ARIC study. J Clin Epidemiol 48 (1995) 927-940
102. Mizushima S., Cappuccio F.P., Nichols R., and Elliot P. Dietary magnesium intake and blood pressure: A qualitative overview of the observational studies. J Hum Hypertens 12 (1998) 447-453
103. Burgess E., Lewanczuk R., Bolli P., Chockalingham A., Cutler H., Taylor G., and Hamet P. Lifestyle modifications to prevent and control hypertension. 6. Recommendations on potassium, magnesium, and calcium. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. CMAJ 160 suppl 9 (1999) 35S-45S
104. Jee S.H., Miller III E.R., Guallar E., Singh V.K., Appel L.J., and Klag M.J. The effect of magnesium supplementation on blood pressure: A meta-analysis of randomized clinical trials. Am J Hypertens 15 (2002) 691-696
105. Dickinson H.O., Nicolson D.J., Campbell F., Cook J.V., Beyer F.R., Ford G.A., and Mason J. Magnesium supplementation for the management of essential hypertension in adults. Cochrane Database Syst Rev 3 (2006) CD004640
106. Gokce N. L-arginine and hypertension. J Nutr 134 suppl (2004) 2807S-2811S
107. Huang P.L., Huang Z., Mashimo H., Block K.D., Moskowitz M.A., Bevan J.A., and Fishman M.C. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377 (1995) 239-242
108. Baylis C., Mitruka B., and Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90 (1992) 278-281
109. Palloshi A., Fragasso G., Piatti P., Monti L.D., Setola E., Valsecchi G., Galluccio E., Chierchia S.L., and Margonato A. Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries. Am J Cardiol 93 (2004) 933-935
110. Huynh H.T., and Tayek J.A. Oral arginine reduces systemic blood pressure in type 2 diabetes: its potential role in nitric oxide generation. J Am Coll Nutr 21 (2002) 422-427
111. Siani A., Pagano E., and Iacone R. Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. Am J Hypertens 13 (2000) 547-551
112. Higashi Y., Oshima T., Ozono R., Watanabe M., Matsuura H., and Kajiyama G. Effects of L-arginine infusion of renal hemodynamics in patients with mild essential hypertension. Hypertension 25 (1995) 898-902
113. Sato K., Kinoshita M., Kojima M., Miyagawa K., Takase H., Suzuki S., and Dohi Y. Failure of L-arginine to induce hypotension with a history of accelerated-malignant hypertension. J Hum Hypertens 14 (2000) 481-483
114. US Department of Agriculture MyPyramid. MyPyramid Web site. http://www.mypyramid.gov/ Accessed February 4, 2007
115. Jena B.S., Jayaprakasha G.K., Singh R.P., and Sakariah K.K. Chemistry and biochemistry of (-)-hydroxycitric acid from Garcinia. J Agric Food Chem 50 (2002) 10-22
116. Tomita K., Okuhara Y., Shigematsu N., Suh H., and Lim K. (-)-Hydroxycitrate ingestion increases fat oxidation during moderate intensity exercise in untrained men. Biosci Biotechnol Biochem 67 (2003) 1999-2001
117. Lim K., Ryu S., Nho H.S., Choi S.K., Kwom T., Suh H., So J., Tomita K., Okuhara Y., and Shigematsu N. (-)-Hydroxycitric acid ingestion increases fat utilization during exercise in untrained women. J Nutr Sci Vitaminol 49 (2003) 163-167 (Tokyo)
118. Westerterp-Plantenga M.S., and Kovacs E.M. The effect of (-)-hydroxycitrate on energy intake and satiety in overweight humans. Int J Obes Relat Metab Disord 26 (2002) 870-872
119. Heymsfield S.B., Allison D.B., Vasselli J.R., Pietrobelli A., Greenfield D., and Nunez C. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: A randomized controlled trial. JAMA 280 (1998) 1596-1600
120. Mattes R.D., and Bormann L. Effects of (-)-hydroxycitric acid on appetitive variables. Physiol Behav 71 (2000) 87-94
121. Preuss H.G., Bagchi D., Bagchi M., Rao C.V., Dey D.K., and Satyanarayana S. Effects of a natural extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and Gymnema sylvestre extract of weight loss. Diabetes Obes Metab 6 (2004) 171-180
122. Cooper R., Morre D.J., and Morre D.M. Medicinal benefits of green tea: Part I. Review of noncancer health benefits. J Altern Complement Med 11 (2005) 521-528
123. Kovacs E.M., and Mela D.J. Metabolically active functional food ingredients for weight control. Obes Rev 7 (2006) 59-78
124. Dulloo A.G., Duret C., Rohrer D., Girardiert L., Mensi N., Fathi M., Chantre P., and Vandermander J. Efficacy of green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr 70 (1999) 1232-1234
125. Chantre P., and Lairon D. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. Phytomedicine 9 (2002) 3-8
126. Nagao T., Komine Y., Soga S., Meguro S., Hase T., Tanaka Y., and Tokimitsu I. Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men. Am J Clin Nutr 81 (2005) 122-129
127. Kovacs E.M., Lejeune M.P., Nijs I., and Westerterp-Plantenga M.S. Effects of green tea on weight maintenance after body-weight loss. Br J Nutr 91 (2004) 431-437
128. Shekelle P.G., Hardy M.L., Morton S.C., Maglione M., Mojica W.A., Suttorp M.J., Rhodes S.L., Jungvig L., and Gagne J. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: A meta-analysis. JAMA 289 (2003) 1537-1545
129. Haller C.A., and Benowitz N.L. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 343 (2000) 1833-1838
130. Hoodoba. Hoodia Gordonii Products Web site. http://www.hoodia-dietpills.com Accessed February 4, 2007
131. Maclean D.B., and Luo L.G. Increased ATP content/production in the hypothalamus may be a signal for energy-sensing of satiety: Studies of the anorectic mechanism of a plant steroidal glycoside. Brain Res 1020 (2004) 1-11